Journal article · 2023 · Open access

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts

Karina E. Pigeaud, Melanie L. Rietveld, Aster F. Witvliet, Jolanda M. A. Hogervorst, Chen Zhang, Tim Forouzanfar, Nathalie Bravenboer, Ton Schoenmaker, Teun J. de Vries

International Journal of Molecular Sciences, 24(8), 7574 · Published 20 April 2023 · DOI 10.3390/ijms24087574

Open PDFView at the publisherCite this paper

In brief

“The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts” is a 2023 journal article by Karina E. Pigeaud and 8 co-authors, published in International Journal of Molecular Sciences. OpenAlex counts 12 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at International Journal of Molecular Sciences.

Citations
12
Most cited in
2025 (4)
Field-weighted impact
0.79
References
44
Authors
9

Abstract

Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and osteoclastogenesis. Here, we assess the role of sclerostin and its clinically used inhibitor, romosozumab, in both processes. For osteogenesis assays, human PDL fibroblasts were cultured under control or mineralizing conditions with increasing concentrations of sclerostin or romosozumab. For analyzing osteogenic capacity and alkaline phosphatase (ALP) activity, alizarin red staining for mineral deposition and qPCR of osteogenic markers were performed. Osteoclast formation was investigated in the presence of sclerostin or romosozumab and, in PDLs, in the presence of fibroblasts co-cultured with peripheral blood mononuclear cells (PBMCs). PDL-PBMC co-cultures stimulated with sclerostin did not affect osteoclast formation. In contrast, the addition of romosozumab slightly reduced the osteoclast formation in PDL-PBMC co-cultures at high concentrations. Neither sclerostin nor romosozumab affected the osteogenic capacity of PDL fibroblasts. qPCR analysis showed that the mineralization medium upregulated the relative expression of osteogenic markers, but this expression was barely affected when romosozumab was added to the cultures. In order to account for the limited effects of sclerostin or romosozumab, we finally compared the expression of SOST and its receptors LRP-4, -5, and -6 to the expression in osteocyte rich-bone. The expression of SOST, LRP-4, and LRP-5 was higher in osteocytes compared to in PDL cells. The limited interaction of sclerostin or romosozumab with PDL fibroblasts may relate to the primary biological function of the periodontal ligament: to primarily resist bone formation and bone degradation to the benefit of an intact ligament that is indented by every chew movement.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Pigeaud, K. E., Rietveld, M. L., Witvliet, A. F., Hogervorst, J. M. A., Zhang, C., Forouzanfar, T., Bravenboer, N., Schoenmaker, T., & de Vries, T. J. (2023). The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts. International Journal of Molecular Sciences, 24(8), 7574. https://doi.org/10.3390/ijms24087574

MLA 9

Pigeaud, Karina E., et al. “The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts.” International Journal of Molecular Sciences, vol. 24, no. 8, 2023, p. 7574. https://doi.org/10.3390/ijms24087574.

Chicago

Pigeaud, Karina E., Melanie L. Rietveld, Aster F. Witvliet, Jolanda M. A. Hogervorst, Chen Zhang, Tim Forouzanfar, Nathalie Bravenboer, Ton Schoenmaker, and Teun J. de Vries. 2023. “The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts.” International Journal of Molecular Sciences 24 (8): 7574. https://doi.org/10.3390/ijms24087574.

Harvard

Pigeaud, K. E. et al. (2023) ‘The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts’, International Journal of Molecular Sciences, 24(8), p. 7574. doi:10.3390/ijms24087574.

IEEE

K. E. Pigeaud et al., “The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts,” International Journal of Molecular Sciences, vol. 24, no. 8, p. 7574, 2023, doi: 10.3390/ijms24087574.

BibTeX

@article{pigeaud2023effect,
  title     = {{The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts}},
  author    = {Pigeaud, Karina E. and Rietveld, Melanie L. and Witvliet, Aster F. and Hogervorst, Jolanda M. A. and Zhang, Chen and Forouzanfar, Tim and Bravenboer, Nathalie and Schoenmaker, Ton and de Vries, Teun J.},
  journal   = {International Journal of Molecular Sciences},
  year      = {2023},
  volume    = {24},
  number    = {8},
  pages     = {7574},
  doi       = {10.3390/ijms24087574},
  url       = {https://doi.org/10.3390/ijms24087574}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202311
202433
202544
202644

Its field-weighted citation impact is 0.79: it has been cited 0.79 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases

  • sclerostin
  • romosozumab
  • periodontal ligament fibroblasts
  • bone formation
  • osteoclastogenesis
  • osteocytes
  • bone formation inhibition
  • periodontal ligament

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Pigeaud, K. E., Rietveld, M. L., Witvliet, A. F., Hogervorst, J. M. A., Zhang, C., Forouzanfar, T., Bravenboer, N., Schoenmaker, T., & de Vries, T. J. (2023). The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts. International Journal of Molecular Sciences, 24(8), 7574. https://doi.org/10.3390/ijms24087574

How many times has this paper been cited?

12 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at International Journal of Molecular Sciences: sign in and open the PDF from this page.

Who wrote this paper?

Karina E. Pigeaud, Melanie L. Rietveld, Aster F. Witvliet, Jolanda M. A. Hogervorst, Chen Zhang, Tim Forouzanfar, Nathalie Bravenboer, Ton Schoenmaker, Teun J. de Vries.

What is the DOI of this paper?

10.3390/ijms24087574, permanently at https://doi.org/10.3390/ijms24087574. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.